References
- First-ever CAR T-cell therapy approved in the U.S. Cancer Discov. 2017;7(10):OF1. doi: 10.1158/2159-8290.CD-NB2017-126
- Carvykti. Highlights of prescribing information. Janssen Biotech Inc; 2022. Accessed August 17, 2020. fda.gov/media/156560/download
- Brenyazi. Highlights of prescribing information. Bristol Myers Squibb; 2022. Accessed August 17, 2020. packageinserts.bms.com/pi/pi_breyanzi.pdf
- Tecartus. Highlights of prescribing information. Kite; 2021. Accessed August 17, 2020. fda.gov/media/140409/download
- Yescarta. Highlights of prescribing information. Kite; 2022. Accessed August 17, 2020. fda.gov/files/vaccines%2C%20blood%20&%20biologics/published/Package-Insert-YESCARTA.pdf
- Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625–638. doi: 10.1016/j.bbmt.2018.12.758
- Baer B. CAR T-cell therapy: updates in nursing management. Clin J Oncol Nurs. 2021;25(3):255–258. doi: 10.1188/21.CJON.255-258
- Jacobson CA, Chavez JC, Sehgal AR, et al. IBCL-124: interim analysis of ZUMA-5: a phase 2 study of axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL). Clin Lymphoma Myeloma Leuk. 2020;20(Suppl 1):S278. doi: 10.1016/s2152-2650(20)30898-3
- Munshi NC, Anderson LD, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705–716. doi: 10.1056/NEJMoa2024850
- Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–2544. doi: 10.1056/nejmoa1707447
- Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45–56. doi: 10.1056/nejmoa1804980
- Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331–1342. doi: 10.1056/nejmoa1914347